Risk of cancer in patients with dermatomyositis or polymyositis and follow-up implications: a Scottish population-based cohort study

Stockton, Diane; Doherty, V.R.; Brewster, David H.

doi:10.1054/bjoc.2001.1699

Cited by 255 publications

(217 citation statements)

References 11 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…Dermatomyositis/ polymyositis was associated strongly with CML. Although these conditions manifest commonly in cancer patients (Stockton et al, 2001), the association with CML remained elevated even when the 5-year period before diagnosis was excluded, indicating that dermatomyositis/polymyositis may also precede CML.…”

Section: Discussionmentioning

confidence: 99%

Risks of myeloid malignancies in patients with autoimmune conditions

et al. 2009

View full text Add to dashboard Cite

Autoimmune conditions are associated with an elevated risk of lymphoproliferative malignancies, but few studies have investigated the risk of myeloid malignancies. From the US Surveillance Epidemiology and End Results (SEER)-Medicare database, 13 486 myeloid malignancy patients (aged 67 þ years) and 160 086 population-based controls were selected. Logistic regression models adjusted for gender, age, race, calendar year and number of physician claims were used to estimate odds ratios (ORs) for myeloid malignancies in relation to autoimmune conditions. Multiple comparisons were controlled for using the Bonferroni correction (Po0.0005).

show abstract

Section: Discussionmentioning

confidence: 99%

Risks of myeloid malignancies in patients with autoimmune conditions

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Thus, the prevalence of cancer in patients with DM ranges from 9.4% to 30% (6) . Furthermore, breast cancer is the third most frequent malignancy in women with DM, and it is found in nearly 10% of cases of malignancyassociated DM (2,3,4,7) . In the majority of reports in the literature, most cancer cases were detected within the first year after DM diagnosis (3) .…”

Section: Discussionmentioning

confidence: 99%

“…This age effect remains still controversial (3) . While Hill et al (2) indicated increased risks of cancer among DM patients younger than 44 years and older than 45 years, Stockton et al (7) indicated that cancer risk decreases with age in DM patients. In contrary, Chen et al (3) demonstrated that the relative risk of cancer in DM remains high in every age group, the fact which highlighted the true link between DM and malignancies despite the age effect.…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer Associated Dermatomyositis: Parallel Occurrence, Remission, and Relapse of the Two Diseases in a Patient: A Case Report

Kouadir

Bouhafa

Mazghi

et al. 2017

IAM

View full text Add to dashboard Cite

Dermatomyositis (DM) is an uncommon inflammatory disease with characteristic cutaneous findings associated with muscle weakness. Although the majority of cases of DM is idiopathic, an increased incidence of underlying malignancy in patients with dermatomyositis has been reported. An underlying breast cancer is found in nearly 10% of cases of malignancy-associated DM. We report a case of a 50-year-old nulliparous woman who was diagnosed with dermatomyositis according to Bohan & Peter criteria. After performing a cancer screening which was negative, the patient was treated with topical and oral corticosteroids; then she was put under immunosuppressors with minimal improvement. One year later, a right breast mass was detected at systemic clinical examination prompting diagnostic workup of breast cancer. After mammogram which showed a suspicious mass, the patient underwent stereotactic breast biopsy which revealed an invasive ductal carcinoma. Computed Tomography (CT) scan of the chest, abdomen, and pelvis and bone scan revealed no distant metastases. The patient underwent mastectomy and axillary dissection followed by adjuvant chemotherapy, radiotherapy, and adjuvant tamoxifen. Simultaneously, she continued the treatment for her Dermatomyositis. Her cutaneous and musculoskeletal symptoms improved dramatically following the treatment of her breast cancer. After four years of uneventful follow-up, the patient reported the recurrence of symptoms suggestive of dermatomyositis. A thoracic-abdominal-pelvic CT scan has been performed and revealed distant metastases. Therefore, our case demonstrates the parallel evolution between dermatomyositis and breast cancer after surgery, local radiotherapy and systemic therapy.

show abstract

“…In a previous study conducted by Hill et al in Sweden, Denmark, and Finland, the most common malignancy was International Classification of Disease (ICD)-7 code 162 or lung, trachea, and bronchus cancers (12). Other studies conducted in Western countries have reported adenocarcinoma of the ovary, lung, or gastrointestinal tract (11,16,43), whereas studies in Southeast Asia, Southern China, and Northern Africa reported high rates of nasopharyngeal carcinoma (16,(44)(45)(46). Regarding the pathological type of malignancy, another study concluded that adenocarcinomas, including lung, ovarian, cervical, gastric, and pancreatic cancers, were most commonly associated with DM (47).…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Profile of Inflammatory Myopathy with Malignancy is Similar to that of Dermatomyositis rather than Polymyositis

et al. 2016

View full text Add to dashboard Cite

Objective An association has been reported between inflammatory myopathies (IMs), which include polymyositis (PM) and dermatomyositis (DM), and malignancy, and the concept of cancer-associated myositis (CAM) was recently proposed. We herein attempted to determine the features and etiologies of these myopathies. Methods We analyzed the gene expression levels via microarray and real-time quantitative reverse transcription polymerase chain reaction analyses to identify genes that were specifically upregulated or downregulated with suspected inflammatory involvement and verified the microarray data via an immunohistochemical (IHC) analysis in additional cases. Patients We selected 14 patients with the following conditions: PM without malignancy (n=3), DM without malignancy (n=3), CAM (n=3), and Controls (no pathological changes or malignancy; n=5). Results PM was distinct from DM and CAM in a clustering analysis and exhibited the highest numbers of overexpressed genes and specific pathologies in a gene ontology analysis. The IHC analysis confirmed the gene expression results. Conclusion PM is associated with severe inflammatory pathological findings, primarily in the cell-mediated immune system. DM and CAM exhibit similarities in the gene expression and IHC results, which suggest that humoral immunity is the main etiology for both myopathies, indicating the importance of cancer screening in patients with IMs, particularly DM.

show abstract

Risk of cancer in patients with dermatomyositis or polymyositis and follow-up implications: a Scottish population-based cohort study

Cited by 255 publications

References 11 publications

Risks of myeloid malignancies in patients with autoimmune conditions

Risks of myeloid malignancies in patients with autoimmune conditions

Breast Cancer Associated Dermatomyositis: Parallel Occurrence, Remission, and Relapse of the Two Diseases in a Patient: A Case Report

Gene Expression Profile of Inflammatory Myopathy with Malignancy is Similar to that of Dermatomyositis rather than Polymyositis

Contact Info

Product

Resources

About